Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) shares crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $8.84 and traded as high as $9.42. Bavarian Nordic shares last traded at $9.33, with a volume of 1,464 shares.
Bavarian Nordic Stock Performance
The firm has a market capitalization of $2.23 billion, a P/E ratio of 11.80 and a beta of 1.36. The business has a 50 day simple moving average of $8.84 and a two-hundred day simple moving average of $8.34.
Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported $0.13 earnings per share for the quarter. The business had revenue of $189.89 million for the quarter. Bavarian Nordic had a return on equity of 11.89% and a net margin of 21.11%. On average, equities analysts anticipate that Bavarian Nordic will post 0.67 earnings per share for the current fiscal year.
About Bavarian Nordic
(
Get Free Report)
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.
Read More
Before you consider Bavarian Nordic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bavarian Nordic wasn't on the list.
While Bavarian Nordic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
